Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY4050784

Small molecule · Inhibitor of SMARCA2 · developed by ELI LILLY &

Phase 1 Most advanced trial
LLY Developer
1 Registered trials

What is LY4050784?

LY4050784 is an orally bioavailable allosteric inhibitor of SMARCA2 (BRM), the ATPase subunit of the SWI/SNF (BAF) chromatin remodeling complex. It is being studied in SMARCA4-deficient tumors, including non-small cell lung cancer, where cancer cells depend on SMARCA2 for survival.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
SMARCA2, SMARCA4 (biomarker)
Mechanism
Inhibitor of SMARCA2
Pathways
SWI/SNF (BAF) chromatin remodeling, transcriptional regulation of oncogenic pathways
Therapy area
Oncology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06561685 Phase 1 Metastatic Solid Tumor Active not recruiting LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung CancerSMARCA4-Deficient Tumor

Other drugs acting on SMARCA2

More from ELI LILLY &

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY4050784

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.